Welcome to our dedicated page for RECURSION PHARMACEUTICALS SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
RXRX submitted Rule 144 resale notices reporting multiple Class A share dispositions by Christopher C. Gibson and affiliated entities. The excerpt lists dated transactions from 04/22/2026 through 07/07/2026 with individual sale sizes and dollar amounts shown, including several 100,000-share entries on 07/01/2026–07/07/2026.
RXRX filed a Form 144 reporting multiple proposed sales of Class A shares by Christopher C. Gibson. The filing lists dated transactions in 2026, including sales of 340,440 shares on 06/18/2026 for $1,089,541.29 and multiple 100,000-share lots in July 2026. The record identifies Founders Shares and brokerage details for the proposed transactions.
RXRX furnished a Form 144 notice relating to Class A founder's shares. The filing lists 40,000 Class A founder's shares under "Securities To Be Sold." The filing also discloses three recent dispositions by Blake C. Borgeson: 30,000 shares on 04/07/2026, 30,000 shares on 05/05/2026, and 30,000 shares on 06/02/2026, each reported with their respective gross proceeds.
RXRX reported an insider sale reported on Form 144 by Christopher C. Gibson. The filing lists multiple dispositions of Class A shares between 04/07/2026 and 07/02/2026, including transactions of 340,440 shares for $1,089,541.29 and two sales of 100,000 shares on 07/01/2026 and 07/02/2026.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Zavain Dar received an award of 5,109 shares of Class A Common Stock. The shares were issued at no cash cost to him and were granted under the company’s Outside Director Compensation Policy. Following this award, he directly holds 240,764 Class A shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li reported an equity award of Class A Common Stock. He received 3,747 shares at $0.0000 per share as compensation under the company’s Outside Director Compensation Policy, increasing his direct holdings to 1,473,329 Class A shares.
In addition to these direct holdings, he is also shown as indirectly holding 421,000 Class A shares through the Dean Y. Li 2021 Family Trust and 1,422,048 Class A shares through the Dean Y. Li Revocable Trust.
RXRX notice reports multiple proposed sales of Class A common stock by Christopher C. Gibson under Rule 144. The notice lists individual sale dates and quantities, including proposed transfers of 40,000 shares on several dates and a 100,000 share entry dated 07/01/2026.
The filing also shows 100,000 Founders Shares granted on 04/20/2021 and identifies Fidelity Brokerage Services LLC as a broker on the filing. Transaction consideration amounts are shown per date in the excerpt.
The issuer submitted a Form 144 disclosing a prospective sale of 100,000 Class A shares tied to restricted stock vesting dated 05/15/2025. The filing lists multiple recent dispositions by Christopher C. Gibson, including a reported 340,440 shares sold for $1,089,541.29 through several trades between 04/07/2026 and 06/18/2026.
Borgeson Blake reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson received a grant of 88,424 shares of Class A common stock in the form of restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholder meeting, subject to his continued service. Following this award, he directly holds 6,258,287 shares.
HERSHBERG ROBERT reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Robert Hershberg received an equity grant of 88,424 shares of Class A Common Stock in the form of restricted stock units. The grant was made at no cash cost under the company’s Outside Director Compensation Policy as a routine award.
These restricted stock units vest on the earlier of June 17, 2027 or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares reported as beneficially owned.